Login to Your Account



Pharnext, Ipsen in $126M Deal for Neuromuscular Compound

By Nuala Moran


Wednesday, June 17, 2009
Drug repositioning specialist Pharnext out-licensed its lead program in the chronic neuromuscular disease, Charcot-Marie-Tooth, to Ipsen SA in a deal with a value of at least €91 million ($US126.1 million). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription